RB1 and neoplasm: Consistent with the results obtained in our xenograft tumor models, treatment with JKE-1674 for 6 weeks inhibited Rb1 loss–driven tumorigenesis in terms of both primary tumor growth and distant metastasis to the lymph node, lung, and liver, as indicated by whole-organ fluorescence imaging (Figure 5B and Supplemental Figure 6D) and comparison of the incidence of metastasis between vehicle- and JKE-1674–treated PPR-RFP mice (Figure 5C).